Xeris Biopharma Holdings (XERS) Accounts Payables (2020 - 2026)

Xeris Biopharma Holdings' Accounts Payables history runs 7 years deep, the most recent figure standing at $11.5 million for Q1 2026.

• Quarterly Accounts Payables rose 80.53% year-over-year to $11.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (up 80.53% YoY) and the FY2025 annual result came in at $3.1 million, up 34.32% from the prior year.
• Accounts Payables was $11.5 million for Q1 2026 at Xeris Biopharma Holdings, up from $3.1 million in the prior quarter.
• Across five years, Accounts Payables topped out at $12.1 million in Q3 2023 and bottomed at $2.3 million in Q4 2024.
• A 5-year average of $7.8 million and a median of $7.1 million in 2024 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2023 — Accounts Payables soared 208.43% — and 2024, when it plunged 80.2%.
• Xeris Biopharma Holdings' Accounts Payables stood at $4.6 million in 2022, then soared by 151.09% to $11.6 million in 2023, then plunged by 80.2% to $2.3 million in 2024, then surged by 34.32% to $3.1 million in 2025, then soared by 272.79% to $11.5 million in 2026.
• Business Quant data shows XERS's Accounts Payables at $11.5 million in Q1 2026, $3.1 million in Q4 2025, and $6.5 million in Q3 2025.